Pioneering the next generation of pattern hair loss innovation

Pattern hair loss (PHL) affects millions of people worldwide—but FDA-approved medications haven’t evolved in 30 years. Veradermics aims to change that.

We were founded to bring clarity, evidence, and real scientific progress to hair loss care.

Pattern hair loss is a medical condition that deserves rigorous evidence, validated therapies, and clear guidance for patients. It’s time to change that.

Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company developing innovative therapeutics for pattern hair loss. We are currently developing investigational product, VDPHL01:

 

  • Designed to be the first oral, non-hormonal FDA-approved therapy for pattern hair loss in men and women.
  • Evaluated through the rigorous, large-scale, placebo-controlled clinical trials designed to assess safety and efficacy.
Not an actual patient
Our mission

To set a new standard in pattern hair loss by developing therapies rooted in rigorous clinical evidence.

Section Separator
Recent news

Pattern hair loss deserves more.

Icon PHL

A profound unmet need

Pattern hair loss transcends mere aesthetics. 
It’s deeply personal, psychological, and essentially universal, yet the standard of care has not meaningfully changed in decades.

Not an actual patient
Icon About Us

Deep roots

Our seasoned management team has long-term experience in dermatology and the pattern hair loss community.

Icon Clinical Trials

Advancing clinical research

Three Phase 3 clinical trials underway in pattern hair loss, marking the first Phase 3 trials for an oral therapy in nearly 30 years and the first ever in the U.S. for female pattern hair loss.

Not an actual patient